Entrada Therapeutics Q4 net loss and EPS beat expectations

Entrada Therapeutics

26/02/2026 12:26

Overview

Biopharmaceutical firm's Q4 net income and EPS beat analyst expectations

Collaboration revenue decreased yr/yr due to completion of VX-670 research

Company expects cash runway into Q3 2027 with $296 mln in cash

Outlook

Entrada expects to report ELEVATE-44-201 Cohort 1 data in Q2 2026

Company anticipates cash runway to last into Q3 2027

Result Drivers

ELEVATE-44-201 STUDY - Initiation of Cohort 2 at increased dose of 12 mg/kg following positive DMC recommendation

CASH POSITION - Expected to fund operations into Q3 2027 with $296 mln in cash and equivalents as of Dec 31, 2025

DMD PROGRAMS - Advancing multiple clinical programs in DMD with four clinical-stage programs expected in 2026

Company press release: ID:nGNX1s7fsq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$1.30 mln
Q4 EPS
Beat
-$0.94
-$1.15 (7 Analysts)
Q4 Net Income
Beat
-$39.16 mln
-$46.16 mln (5 Analysts)
Q4 Income From Operations
-$42.21 mln
Q4 Operating Expenses
$43.51 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Entrada Therapeutics Inc is $20.00, about 66.9% above its February 25 closing price of $11.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)